These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 17976204)

  • 1. Glycaemic responsiveness to long-term insulin plus sulphonylurea therapy as assessed by sulphonylurea withdrawal.
    Nybäck-Nakell A; Adamson U; Lins PE; Landstedt-Hallin L
    Diabet Med; 2007 Dec; 24(12):1424-9. PubMed ID: 17976204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of sulphonylurea in combination therapy assessed in a trial of sulphonylurea withdrawal. Scandinavian Insulin-Sulphonylurea Study Group Research Team.
    Landstedt-Hallin L; Arner P; Lins PE; Bolinder J; Olsen H; Groop L
    Diabet Med; 1999 Oct; 16(10):827-34. PubMed ID: 10547209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.
    Hamann A; Garcia-Puig J; Paul G; Donaldson J; Stewart M
    Exp Clin Endocrinol Diabetes; 2008 Jan; 116(1):6-13. PubMed ID: 18095238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Earlier triple therapy with pioglitazone in patients with type 2 diabetes.
    Charpentier G; Halimi S;
    Diabetes Obes Metab; 2009 Sep; 11(9):844-54. PubMed ID: 19614944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosiglitazone RECORD study: glucose control outcomes at 18 months.
    Home PD; Jones NP; Pocock SJ; Beck-Nielsen H; Gomis R; Hanefeld M; Komajda M; Curtis P;
    Diabet Med; 2007 Jun; 24(6):626-34. PubMed ID: 17517066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreasing postprandial C-peptide levels over time are not associated with long-term use of sulphonylurea: an observational study.
    Nybäck-Nakell A; Bergström J; Adamson U; Lins PE; Landstedt-Hallin L
    Diabetes Metab; 2010 Nov; 36(5):375-80. PubMed ID: 20579917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.
    Blonde L; Merilainen M; Karwe V; Raskin P;
    Diabetes Obes Metab; 2009 Jun; 11(6):623-31. PubMed ID: 19515182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17).
    Scheen AJ; Tan MH; Betteridge DJ; Birkeland K; Schmitz O; Charbonnel B;
    Diabet Med; 2009 Oct; 26(10):1033-9. PubMed ID: 19900236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
    Owens DR; Swallow R; Dugi KA; Woerle HJ
    Diabet Med; 2011 Nov; 28(11):1352-61. PubMed ID: 21781152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing hormonal and symptomatic responses to experimental hypoglycaemia in insulin- and sulphonylurea-treated Type 2 diabetes.
    Choudhary P; Lonnen K; Emery CJ; MacDonald IA; MacLeod KM; Amiel SA; Heller SR
    Diabet Med; 2009 Jul; 26(7):665-72. PubMed ID: 19573114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea.
    Garber AJ; Foley JE; Banerji MA; Ebeling P; Gudbjörnsdottir S; Camisasca RP; Couturier A; Baron MA
    Diabetes Obes Metab; 2008 Nov; 10(11):1047-56. PubMed ID: 18284434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive characteristics of patients achieving glycaemic control with insulin after sulfonylurea failure.
    Lee YH; Lee BW; Chun SW; Cha BS; Lee HC
    Int J Clin Pract; 2011 Oct; 65(10):1076-84. PubMed ID: 21923847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study.
    Alvarez Guisasola F; Mavros P; Nocea G; Alemao E; Alexander CM; Yin D
    Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():8-15. PubMed ID: 18435669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of acarbose on additional insulin therapy in type 2 diabetic patients with late failure of sulphonylurea therapy.
    Standl E; Baumgartl HJ; Füchtenbusch M; Stemplinger J
    Diabetes Obes Metab; 1999 Jul; 1(4):215-20. PubMed ID: 11228756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of standard test meal in initiation of insulin therapy in type 2 diabetes].
    Koprivica B; Beljić-Zivković T; Ille T
    Srp Arh Celok Lek; 2009; 137(9-10):490-6. PubMed ID: 19950754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with type 2 diabetes and exposure to hepatitis B or C.
    Zhu XX; Pan CY; Li GW; Shi HL; Tian H; Yang WY; Jiang J; Sun XC; Davies C; Chow WH
    Diabetes Technol Ther; 2003; 5(1):33-42. PubMed ID: 12725705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials.
    Rajagopalan R; Xu Y; Abbadessa M;
    Am J Geriatr Pharmacother; 2006 Jun; 4(2):123-33. PubMed ID: 16860259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.
    Hanefeld M; Brunetti P; Schernthaner GH; Matthews DR; Charbonnel BH;
    Diabetes Care; 2004 Jan; 27(1):141-7. PubMed ID: 14693980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care.
    Cook MN; Girman CJ; Stein PP; Alexander CM
    Diabet Med; 2007 Apr; 24(4):350-8. PubMed ID: 17335466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.